Ehave, Inc. To Sponsor Major Psychedelics Conference, Wonderland: Miami

0
25

Wonderland: Miami is hosted by Microdose and engages some of the greatest minds in the Psychedelic Sector, by fostering creative and professional growth

Miami, Florida–(Newsfile Corp. – November 5, 2021) –  Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today that it will participate in Microdose’s Wonderland: Miami Conference to be held at the Adrienne Arsht Center for the Performing Arts in Miami, FL on November 7-9, 2021.

“”We are pleased to have the opportunity to participate as a sponsor for the Wonderland: Miami conference. Having this opportunity to sponsor Wonderland: Miami is a great opportunity for Ehave and its shareholders as we progress into the next phase of our business plan,” said Ben Kaplan, CEO of Ehave. Mr. Kaplan continued, “We look forward to the opportunity to create new relationships with industry leaders, as well as the opportunity to deepen our existing relationships with our existing partners in attendance.”

Wonderland: Miami features 30 programming tracks, panels, fireside chats, networking, and speakers such as:

  • Dr. Robin Carhart-Harris, PhD – Ralph Metzner Distinguished Professor of Neurology & Psychiatry, Director Psychedelics Division, Neuroscape, University of California, San Francisco
  • Matthew Johnson – Susan Hill Ward Professor of Psychedelics and Consciousness, Johns Hopkins University School of Medicine
  • Deborah Mash, PhD
  • CEO & Founder – DemeRx
  • Rick Doblin- Executive Director, MAPS
  • Jayashree Mitra – Partner, Zuber Lawler
  • David Nutt – Chief Research Officer, Awakn Life Sciences
  • Ben Sessa – Chief Medical Officer, Awakn Life Sciences
  • Daniel Carcillo – Founder / Activist, Wesana Health, Chapter 5 Foundation
  • Lynn Marie Morski – President, Psychedelic Medicine Association
  • Zappy Zapolin – Psychedelic Concierge

Wonderland: Miami will also feature sports icons like Mike Tyson, Lamar Odom and Anna Symonds, who will be in attendance to share their stories.

For more information about the event, or to schedule a one-on-one meeting with Ehave, Inc., please contact us at info@ehave.com.

About Ehave, Inc.

Ehave, Inc. is a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, psychedelics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes meeting privacy and HIPAA & GDPR Compliant. Our main product is the Ehave Dashboard which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insight using Blockchain technology. The Ehave dashboard offers Offline Encrypted Digital Records Empowering Healthcare providers and patients and it’s a powerful machine learning and artificial intelligence platform using artificial intelligence to extract deep insights from audio, video and text to improve research with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools.

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading “Risk Factors” in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC’s website, http://www.sec.gov.

For Investors Relations, please contact:

Gabe Rodriguez
Phone: (623) 261-9046
Email: ir@ehave.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/102127

LEAVE A REPLY

Please enter your comment!
Please enter your name here